|
CN103153284B
(zh)
|
2010-07-06 |
2015-11-25 |
诺华股份有限公司 |
含有其pKa值有利于RNA递送的脂质的脂质体
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするrnaの送達のためのpeg化リポソーム
|
|
KR102266691B1
(ko)
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
EP3722277A3
(en)
|
2013-10-04 |
2021-01-20 |
Novartis AG |
3'end caps for rna-interferring agents for use in rna
|
|
WO2015050871A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compounds to treat hepatitis b virus
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
JP2017100988A
(ja)
*
|
2015-12-01 |
2017-06-08 |
アサヒグループホールディングス株式会社 |
光学活性なヒドロキシ脂肪酸の製造方法
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
MX2018007987A
(es)
|
2015-12-28 |
2019-01-10 |
Novartis Ag |
Composiciones y metodos para el tratamiento de hemoglobinopatias.
|
|
WO2017120504A1
(en)
|
2016-01-08 |
2017-07-13 |
Durfee Paul N |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
|
CN109069440A
(zh)
|
2016-03-02 |
2018-12-21 |
得克萨斯州大学系统董事会 |
用于免疫治疗的激活sting的纳米疫苗
|
|
ES3030658T3
(en)
*
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
JP2019515914A
(ja)
|
2016-04-22 |
2019-06-13 |
インテリア セラピューティクス,インコーポレイテッド |
転写因子4内のトリヌクレオチドリピートと関連する疾患の治療のための組成物および方法
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
CN109562153A
(zh)
|
2016-08-07 |
2019-04-02 |
诺华股份有限公司 |
mRNA介导的免疫方法
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
EP3541416A1
(en)
|
2016-11-17 |
2019-09-25 |
GlaxoSmithKline Biologicals SA |
Zika viral antigen constructs
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
US11344629B2
(en)
|
2017-03-01 |
2022-05-31 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
|
WO2018170260A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018206168A1
(en)
*
|
2017-05-11 |
2018-11-15 |
Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh |
Concept for the treatment of monogenetic disorders
|
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
BR112019025104A2
(pt)
*
|
2017-05-30 |
2020-06-23 |
Glaxosmithkline Biologicals S.A. |
Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
US10780183B2
(en)
|
2017-06-19 |
2020-09-22 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of Friedreich's ataxia
|
|
CN111108203A
(zh)
|
2017-07-17 |
2020-05-05 |
葛兰素史密丝克莱恩生物有限公司 |
狂犬病病毒抗原构建体
|
|
WO2019028387A1
(en)
*
|
2017-08-03 |
2019-02-07 |
Rita Elena Serda |
LIPOSOMAL COATED NANOPARTICLES FOR IMMUNOTHERAPY APPLICATIONS
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
CA3077391A1
(en)
*
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
In vitro method of mrna delivery using lipid nanoparticles
|
|
IL311278B2
(en)
|
2017-09-29 |
2026-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing
|
|
EP3688162B1
(en)
*
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
TWI904069B
(zh)
|
2017-09-29 |
2025-11-11 |
美商英特利亞醫療公司 |
用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
|
|
EP3793689A1
(en)
|
2018-05-15 |
2021-03-24 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
US12076439B2
(en)
|
2018-05-24 |
2024-09-03 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
MA52762A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques comprenant une fraction stéroïdienne
|
|
AU2019277355A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
EP3802507A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
CN118436618A
(zh)
|
2018-05-30 |
2024-08-06 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
|
CN112399860B
(zh)
|
2018-06-06 |
2024-08-16 |
麻省理工学院 |
用于在真核细胞中翻译的环状rna
|
|
ES2964547T3
(es)
|
2018-06-08 |
2024-04-08 |
Fujifilm Corp |
Compuesto, sal del mismo y partículas lipídicas
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
US10736847B2
(en)
|
2018-07-03 |
2020-08-11 |
Becton, Dickinson And Company |
Inverting device for liposome preparation by centrifugation
|
|
WO2020023533A1
(en)
|
2018-07-23 |
2020-01-30 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
|
WO2020032184A1
(ja)
*
|
2018-08-10 |
2020-02-13 |
武田薬品工業株式会社 |
カチオン性脂質
|
|
JP7436990B2
(ja)
|
2018-08-10 |
2024-02-22 |
国立大学法人京都大学 |
カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
|
|
AU2019321186B2
(en)
|
2018-08-17 |
2024-05-23 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
EP3843709A1
(en)
|
2018-08-29 |
2021-07-07 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12252708B2
(en)
|
2018-09-24 |
2025-03-18 |
Unm Rainforest Innovations |
Living mammalian cells modified with functional modular nanoparticles
|
|
MX2021003455A
(es)
*
|
2018-10-02 |
2021-09-21 |
Intellia Therapeutics Inc |
Lípidos con amina ionizables.
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス,インコーポレーテッド |
第ix因子を発現するための組成物及び方法
|
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
|
CN112888451A
(zh)
|
2018-10-19 |
2021-06-01 |
川斯勒佰尔公司 |
信使rna的无泵包封
|
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
CA3117866A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
WO2020097379A2
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
KR102860605B1
(ko)
|
2018-11-09 |
2025-09-15 |
트랜슬레이트 바이오 인코포레이티드 |
에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
|
|
EP3880174A2
(en)
|
2018-11-12 |
2021-09-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
US12257305B2
(en)
|
2018-11-21 |
2025-03-25 |
Translate Bio, Inc. |
Cationic lipid compounds
|
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
EP3886901A1
(en)
|
2018-11-29 |
2021-10-06 |
GlaxoSmithKline Biologicals S.A. |
Methods for manufacturing an adjuvant
|
|
CN119285480A
(zh)
|
2018-12-05 |
2025-01-10 |
英特利亚治疗股份有限公司 |
改性的胺脂质
|
|
EP3893927A1
(en)
|
2018-12-14 |
2021-10-20 |
GlaxoSmithKline Biologicals S.A. |
Heterologous prime boost vaccine compositions and methods
|
|
WO2020146344A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
WO2020176716A1
(en)
|
2019-02-28 |
2020-09-03 |
Brinker C Jeffrey |
Modular metal–organic polyhedra superassembly compositions
|
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
|
KR20220004648A
(ko)
|
2019-03-28 |
2022-01-11 |
인텔리아 테라퓨틱스, 인크. |
Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
|
|
MX2021011690A
(es)
|
2019-03-28 |
2022-01-06 |
Intellia Therapeutics Inc |
Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
|
|
MX2021011757A
(es)
|
2019-03-28 |
2021-12-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la expresión de polipéptidos.
|
|
WO2020214946A1
(en)
|
2019-04-18 |
2020-10-22 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
EP3959195B1
(en)
|
2019-04-22 |
2023-11-08 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
WO2020219876A1
(en)
*
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
WO2020227085A1
(en)
|
2019-05-03 |
2020-11-12 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
JP7686574B2
(ja)
|
2019-05-22 |
2025-06-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状rna組成物及び方法
|
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
CA3143865A1
(en)
*
|
2019-06-07 |
2020-12-10 |
Fujifilm Corporation |
Lipid composition
|
|
US20220259617A1
(en)
|
2019-06-13 |
2022-08-18 |
The General Hospital Corporation |
Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
|
|
EP3986858A1
(en)
|
2019-06-21 |
2022-04-27 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
CA3146369A1
(en)
|
2019-07-08 |
2021-01-14 |
Translate Bio, Inc. |
Improved mrna-loaded lipid nanoparticles and processes of making the same
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
MX2022000879A
(es)
|
2019-07-21 |
2022-05-02 |
Glaxosmithkline Biologicals Sa |
Vacuna viral terapeutica.
|
|
AU2020315962B2
(en)
|
2019-07-23 |
2026-02-12 |
Translate Bio, Inc. |
Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
|
|
JP7600208B2
(ja)
*
|
2019-07-29 |
2024-12-16 |
ジョージア テック リサーチ コーポレイション |
拘束された脂質を含むナノ材料およびその使用
|
|
US12642889B2
(en)
|
2019-08-30 |
2026-06-02 |
Northwestern University |
Biodegradable soft elastomers for regenerative engineering
|
|
WO2021038508A1
(en)
|
2019-08-30 |
2021-03-04 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
JP2023500794A
(ja)
*
|
2019-10-17 |
2023-01-11 |
エーアイ‐バイオファーマ |
抗ウイルス薬および肝臓標的薬
|
|
EP4048316A1
(en)
|
2019-10-21 |
2022-08-31 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
EP4059505B1
(en)
*
|
2019-11-15 |
2024-02-21 |
FUJIFILM Corporation |
Lipid composition
|
|
MX2022006854A
(es)
|
2019-12-04 |
2022-11-30 |
Orna Therapeutics Inc |
Composiciones y metodos de arn circular.
|
|
JP7699128B2
(ja)
*
|
2019-12-06 |
2025-06-26 |
ガイド セラピューティクス,エルエルシー |
ナノマテリアル
|
|
WO2021117769A1
(ja)
*
|
2019-12-10 |
2021-06-17 |
富士フイルム株式会社 |
医薬組成物及び処置剤
|
|
WO2021117770A1
(ja)
*
|
2019-12-10 |
2021-06-17 |
富士フイルム株式会社 |
医薬組成物及び処置剤
|
|
JP7846007B2
(ja)
|
2019-12-18 |
2026-04-14 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物及び方法
|
|
MX2022007756A
(es)
|
2019-12-20 |
2022-09-27 |
Translate Bio Inc |
Suministro rectal de arn mensajero.
|
|
JP2023508881A
(ja)
|
2019-12-20 |
2023-03-06 |
トランスレイト バイオ, インコーポレイテッド |
Mrna担持脂質ナノ粒子を調製する改善されたプロセス
|
|
CN115175894B
(zh)
*
|
2020-01-09 |
2024-09-06 |
盖德治疗有限责任公司 |
纳米材料
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
CN115362256A
(zh)
|
2020-02-07 |
2022-11-18 |
因特利亚治疗公司 |
用于激肽释放酶(klkb1)基因编辑的组合物和方法
|
|
CN115427021A
(zh)
|
2020-02-25 |
2022-12-02 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
|
BR112022017715A2
(pt)
|
2020-03-04 |
2022-11-16 |
Flagship Pioneering Innovations Vi Llc |
Métodos e composições para modular um genoma
|
|
CA3174708A1
(en)
*
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
JP7709981B2
(ja)
*
|
2020-03-17 |
2025-07-17 |
ジェネヴァント サイエンシズ ゲーエムベーハー |
肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
|
|
US20240245805A1
(en)
|
2020-03-20 |
2024-07-25 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for therapeutic expression of factor ix
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
US12115230B2
(en)
|
2020-04-09 |
2024-10-15 |
Verve Therapeutics, Inc. |
Base editing of ANGPTL3 and methods of using same for treatment of disease
|
|
EP4132951A4
(en)
|
2020-04-09 |
2025-06-11 |
Verve Therapeutics, Inc. |
CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
|
|
US20230364219A1
(en)
|
2020-04-16 |
2023-11-16 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
AU2021269042A1
(en)
|
2020-05-07 |
2023-02-02 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding SARS-CoV-2 antigens
|
|
AU2021269137A1
(en)
*
|
2020-05-08 |
2022-12-15 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
ES3066134T3
(en)
|
2020-05-14 |
2026-05-11 |
Translate Bio Inc |
Peg lipidoid compounds
|
|
JP7873638B2
(ja)
|
2020-05-15 |
2026-06-12 |
トランスレイト バイオ, インコーポレイテッド |
mRNA送達のための脂質ナノ粒子製剤
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
US20230203510A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
EP4171629A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
BR112023001272A2
(pt)
|
2020-07-24 |
2023-04-04 |
Massachusetts Gen Hospital |
Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
|
|
MX2023001109A
(es)
|
2020-07-27 |
2023-04-24 |
Anjarium Biosciences Ag |
Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
JP7518909B2
(ja)
|
2020-09-14 |
2024-07-18 |
富士フイルム株式会社 |
脂質組成物
|
|
WO2022060871A1
(en)
*
|
2020-09-15 |
2022-03-24 |
Verve Therapeutics, Inc. |
Lipid formulations for gene editing
|
|
JP7844452B2
(ja)
*
|
2020-09-23 |
2026-04-13 |
トランスレイト バイオ, インコーポレイテッド |
Tesベースのカチオン性脂質
|
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
|
US12678406B2
(en)
|
2020-10-12 |
2026-07-14 |
Translate Bio Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
CA3198411A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US12576030B2
(en)
|
2020-11-09 |
2026-03-17 |
Translate Bio, Inc. |
Compositions for delivery of codon-optimized mRNA
|
|
JP7872268B2
(ja)
|
2020-11-25 |
2026-06-09 |
トランスレイト バイオ, インコーポレイテッド |
安定な液状脂質ナノ粒子製剤
|
|
EP4259792A1
(en)
|
2020-12-11 |
2023-10-18 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
CN116887841A
(zh)
*
|
2020-12-21 |
2023-10-13 |
比姆医疗股份有限公司 |
包括酯连接缩醛的纳米材料
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
JP2024502036A
(ja)
|
2020-12-30 |
2024-01-17 |
インテリア セラピューティクス,インコーポレイテッド |
操作されたt細胞
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
CN116761888A
(zh)
|
2021-01-20 |
2023-09-15 |
比姆医疗股份有限公司 |
纳米材料
|
|
AU2022210299A1
(en)
*
|
2021-01-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable lipids for nanomaterials
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
EP4281080A4
(en)
*
|
2021-01-20 |
2025-09-24 |
Beam Therapeutics Inc |
NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
|
|
US20240123076A1
(en)
|
2021-02-08 |
2024-04-18 |
The Board Of Regents Of The University Of Texas System |
Unsaturated dendrimers compositions, related formulations, and methods of use thereof
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
MX2023010461A
(es)
*
|
2021-03-08 |
2023-09-14 |
Eyegene Inc |
Composicion para la entrega in vivo de arn y metodo de preparacion para la misma.
|
|
MX2023011227A
(es)
|
2021-03-22 |
2023-12-06 |
Recode Therapeutics Inc |
Composiciones y metodos para administracion dirigida a celulas.
|
|
MX2023011243A
(es)
|
2021-03-23 |
2023-12-14 |
Recode Therapeutics Inc |
Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
|
|
US20250268994A1
(en)
|
2021-03-25 |
2025-08-28 |
Translate Bio, Inc. |
Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
|
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
CA3216873A1
(en)
|
2021-04-17 |
2022-10-22 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
US20240300977A1
(en)
|
2021-04-17 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Inhibitors of dna-dependent protein kinase and compositions and uses thereof
|
|
EP4322920A1
(en)
|
2021-04-17 |
2024-02-21 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスdnaベクター及びその使用
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022259191A1
(en)
|
2021-06-09 |
2022-12-15 |
Glaxosmithkline Biologicals Sa |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
AU2022288705A1
(en)
|
2021-06-10 |
2023-12-07 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202317764A
(zh)
|
2021-06-10 |
2023-05-01 |
美商英特利亞醫療公司 |
用於基因編輯之包含內部連接子之經修飾引導rna
|
|
MX2023014774A
(es)
|
2021-06-11 |
2024-01-15 |
Bayer Ag |
Nuevos sistemas de endonucleasas programables de arn tipo v.
|
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
|
WO2022271780A1
(en)
|
2021-06-22 |
2022-12-29 |
Intellia Therapeutics, Inc. |
Methods for in vivo editing of a liver gene
|
|
US20250127809A1
(en)
|
2021-06-23 |
2025-04-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
EP4380576A4
(en)
*
|
2021-08-03 |
2026-04-29 |
Verve Therapeutics Inc |
RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
|
|
US20250134824A1
(en)
|
2021-08-16 |
2025-05-01 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
US20240350410A1
(en)
|
2021-08-16 |
2024-10-24 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023031855A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
|
KR20260037664A
(ko)
|
2021-09-08 |
2026-03-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
게놈을 조절하기 위한 방법 및 조성물
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
US20250268828A1
(en)
|
2021-09-30 |
2025-08-28 |
Orna Therapeutics, Inc. |
Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides
|
|
JP7883580B2
(ja)
*
|
2021-10-08 |
2026-07-01 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
EP4419706A1
(en)
|
2021-10-18 |
2024-08-28 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
EP4426822A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
JP2024545572A
(ja)
|
2021-11-10 |
2024-12-10 |
トランスレイト バイオ, インコーポレイテッド |
原発性線毛機能不全の治療のための組成物及び方法
|
|
US20250002941A1
(en)
|
2021-11-23 |
2025-01-02 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
MX2024006407A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de inmunogenos del virus varicela-zoster y sus usos.
|
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
US20250223584A2
(en)
|
2021-12-03 |
2025-07-10 |
The Broad Institute, Inc. |
Compositions and methods for efficient in vivo delivery
|
|
CN118510896A
(zh)
|
2021-12-17 |
2024-08-16 |
旗舰创业创新六公司 |
用于在变性条件下富集环状rna的方法
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
WO2023121971A1
(en)
*
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterials comprising tetravalent lipid compounds
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
EP4453191A1
(en)
|
2021-12-23 |
2024-10-30 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
EP4466029A1
(en)
|
2022-01-21 |
2024-11-27 |
Orna Therapeutics, Inc. |
Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes
|
|
CN114105799B
(zh)
*
|
2022-01-25 |
2022-05-10 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其制备方法和应用
|
|
IL314482A
(en)
|
2022-02-02 |
2024-09-01 |
Regeneron Pharma |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
EP4493212A1
(en)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4494644A4
(en)
|
2022-03-15 |
2025-06-11 |
FUJIFILM Corporation |
LIPID COMPOSITION
|
|
CN116120198B
(zh)
*
|
2022-03-21 |
2024-03-15 |
苏州科锐迈德生物医药科技有限公司 |
具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
CA3245624A1
(en)
|
2022-03-25 |
2023-09-28 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
|
|
CN116354836A
(zh)
*
|
2022-03-25 |
2023-06-30 |
深圳市新合生物医疗科技有限公司 |
阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー |
ワクチン及び関連する方法
|
|
AU2023269134A1
(en)
|
2022-05-09 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー |
二本鎖dna組成物及び関連する方法
|
|
JP2025519070A
(ja)
|
2022-05-17 |
2025-06-24 |
エンヴェロップ セラピューティクス, インコーポレイテッド |
効率的in vivo送達のための組成物および方法
|
|
WO2023230601A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
Identification of nanoparticles for preferential tissue or cell targeting
|
|
US20250325492A1
(en)
*
|
2022-06-03 |
2025-10-23 |
University Of Cincinnati |
Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
KR20250042143A
(ko)
*
|
2022-06-23 |
2025-03-26 |
턴 바이오테크놀로지스 인코포레이티드 |
지질 구조 및 이를 포함하는 조성물
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
EP4540222A1
(en)
*
|
2022-07-20 |
2025-04-23 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
|
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024078614A1
(zh)
*
|
2022-10-13 |
2024-04-18 |
深圳深信生物科技有限公司 |
用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
US20260207525A1
(en)
|
2022-12-01 |
2026-07-23 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
IL321026A
(en)
|
2022-12-08 |
2025-07-01 |
Recode Therapeutics Inc |
Nanoparticle formulations and their uses
|
|
US20260209732A1
(en)
|
2022-12-13 |
2026-07-23 |
Bayer Aktiengesellschaft |
Engineered type v rna programmable endonucleases and their uses
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
KR102921785B1
(ko)
*
|
2022-12-19 |
2026-02-03 |
주식회사 녹십자 |
핵산 전달용 사이클로알칸계 지질 화합물 및 이를 포함하는 지질 나노입자
|
|
TW202438514A
(zh)
|
2022-12-20 |
2024-10-01 |
法商賽諾菲公司 |
鼻病毒mrna疫苗
|
|
EP4638783A2
(en)
|
2022-12-22 |
2025-10-29 |
Intellia Therapeutics, Inc. |
Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
US20260209255A1
(en)
*
|
2022-12-23 |
2026-07-23 |
Turn Biotechnologies, Inc. |
Dual lipid structures
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
JP2026503676A
(ja)
|
2023-01-27 |
2026-01-29 |
セイル バイオメディシンズ インコーポレイテッド |
修飾脂質組成物およびその使用
|
|
CN120641396A
(zh)
*
|
2023-01-29 |
2025-09-12 |
正基基因科技有限公司 |
阳离子脂质与脂质纳米颗粒
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節組合物及相關方法
|
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
TW202446956A
(zh)
|
2023-02-17 |
2024-12-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
包含經修飾的胞嘧啶的dna組成物
|
|
KR20250151437A
(ko)
|
2023-02-17 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
변형된 우라실을 포함하는 dna 조성물
|
|
EP4680276A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
MX2025012337A
(es)
|
2023-04-17 |
2026-02-03 |
Sanofi Pasteur Inc |
Formulaciones de polvo seco reconstituibles y métodos de uso de las mismas
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
EP4698150A1
(en)
|
2023-04-19 |
2026-02-25 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
JP2026518411A
(ja)
|
2023-04-27 |
2026-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
TW202511244A
(zh)
*
|
2023-04-28 |
2025-03-16 |
日商日東電工股份有限公司 |
脂質及包含其之醫藥組合物、以及傳遞活性醫藥成分之方法
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP2026523341A
(ja)
|
2023-05-15 |
2026-07-14 |
エヌクロマ・バイオ,インコーポレーテッド |
Hbv遺伝子発現のエピジェネティック調節のための組成物および方法
|
|
TW202502729A
(zh)
|
2023-05-19 |
2025-01-16 |
美商英特利亞醫療公司 |
可電離胺脂質
|
|
EP4719352A1
(en)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
WO2025019352A2
(en)
*
|
2023-07-14 |
2025-01-23 |
Modernatx, Inc. |
Mers-cov mrna vaccines
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
AR133384A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025038864A1
(en)
*
|
2023-08-16 |
2025-02-20 |
Beam Therapeutics Inc. |
Ionizable lipids with linear head groups
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
EP4771042A1
(en)
|
2023-08-29 |
2026-07-08 |
Shanghai Circode Biomed Co., Ltd |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
IL327035A
(en)
|
2023-09-18 |
2026-05-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipidoid compositions and their medical uses
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025076113A1
(en)
*
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
TW202521691A
(zh)
|
2023-10-06 |
2025-06-01 |
美商藍岩醫療公司 |
經工程化之v型rna可程式核酸內切酶及其用途
|
|
WO2025081002A1
(en)
*
|
2023-10-11 |
2025-04-17 |
RNAimmune, Inc. |
Ionizable lipids for the delivery of nucleic acids
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
CN122497525A
(zh)
|
2023-11-07 |
2026-07-31 |
欧纳医疗公司 |
环状rna组合物
|
|
KR20260113064A
(ko)
|
2023-11-14 |
2026-07-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
이온화 가능한 리피도이드 조성물 및 이의 치료적 용도
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
FR3155424A1
(fr)
|
2023-11-15 |
2025-05-23 |
BioNTech SE |
Compositions immunogènes contre le sars-cov-2
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117969A1
(en)
|
2023-12-01 |
2025-06-05 |
Orna Therapeutics, Inc. |
Process for manufacturing lipid nanoparticles
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US12553042B2
(en)
|
2023-12-01 |
2026-02-17 |
Recode Therapeutics, Inc. |
Method for quantifying an amount of capped messenger RNA
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
IL330230A
(en)
|
2023-12-20 |
2026-08-01 |
Intellia Therapeutics Inc |
Engineered T cells
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
AU2024412236A1
(en)
|
2023-12-28 |
2026-07-09 |
Fujifilm Corporation |
Method for delivering nucleic acid to immune cells, agent for delivering nucleic acid to immune cells, and use thereof
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
AU2025217182A1
(en)
|
2024-02-02 |
2026-08-06 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025212932A1
(en)
*
|
2024-04-03 |
2025-10-09 |
Intellia Therapeutics, Inc. |
Methods of synthesizing amine lipids
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217131A1
(en)
*
|
2024-04-08 |
2025-10-16 |
Popvax Private Limited |
Novel lipids for delivery of nucleic acid therapeutics
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
TW202613158A
(zh)
|
2024-05-16 |
2026-04-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
TW202617987A
(zh)
|
2024-06-26 |
2026-05-01 |
美商英特利亞醫療公司 |
用於基因體編輯之經修飾之嚮導rna
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026006579A1
(en)
*
|
2024-06-27 |
2026-01-02 |
Innovac Therapeutics Hk Limited |
Ether-containing novel ionizable lipids and their uses thereof
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
TW202606646A
(zh)
*
|
2024-07-04 |
2026-02-16 |
日商日東電工股份有限公司 |
非對稱結構脂質
|
|
WO2026033123A1
(en)
|
2024-08-08 |
2026-02-12 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026096919A1
(en)
|
2024-11-01 |
2026-05-07 |
Sail Biomedicines, Inc. |
Novel dipepetide core lipids, lipid carriers, and methods of using thereof
|
|
WO2026097018A1
(en)
|
2024-11-04 |
2026-05-07 |
Intellia Therapeutics, Inc. |
Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers
|
|
WO2026102108A1
(en)
|
2024-11-07 |
2026-05-15 |
Flagship Pioneering Innovations Vii, Llc |
Dna production methods
|
|
WO2026102260A1
(en)
|
2024-11-08 |
2026-05-15 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
|
|
WO2026119817A1
(en)
|
2024-12-02 |
2026-06-11 |
BioNTech SE |
Agents and methods for targeted delivery of immune effector cells
|
|
WO2026122685A1
(en)
|
2024-12-03 |
2026-06-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2026122747A2
(en)
|
2024-12-05 |
2026-06-11 |
Flagship Pioneering Innovations Vii, Llc |
Novel immunomodulatory proteins and related methods
|
|
WO2026125590A1
(en)
|
2024-12-13 |
2026-06-18 |
BioNTech SE |
Measuring nucleic acid integrity
|
|
WO2026125598A1
(en)
|
2024-12-13 |
2026-06-18 |
BioNTech SE |
Measuring nucleic acid integrity
|
|
WO2026134325A1
(ja)
*
|
2024-12-20 |
2026-06-25 |
武田薬品工業株式会社 |
カチオン性脂質
|
|
WO2026139456A2
(en)
|
2024-12-23 |
2026-07-02 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna molecules
|
|
WO2026145583A1
(en)
*
|
2024-12-31 |
2026-07-09 |
Everest Medicines (China) Co., Ltd. |
Ionizable lipid compounds and compositions, preparations, and uses thereof
|
|
WO2026148356A1
(en)
|
2025-01-06 |
2026-07-09 |
BioNTech SE |
Coronavirus and influenza immunogenic combinations
|
|
WO2026152023A1
(en)
|
2025-01-10 |
2026-07-16 |
Sail Biomedicines, Inc. |
Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides
|
|
WO2026151879A1
(en)
|
2025-01-10 |
2026-07-16 |
Flagship Pioneering Innovations Vii, Llc |
Vaccine compositions and methods
|
|
WO2026150132A1
(en)
|
2025-01-12 |
2026-07-16 |
BioNTech SE |
Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
|
|
WO2026152164A1
(en)
|
2025-01-13 |
2026-07-16 |
Sail Biomedicines, Inc. |
Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo
|
|
WO2026161677A1
(en)
|
2025-01-24 |
2026-07-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026161895A1
(en)
|
2025-01-27 |
2026-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
|
|
WO2026162682A1
(en)
|
2025-01-29 |
2026-08-06 |
BioNTech SE |
Compositions for delivery of plasmodium rh5 antigens and related methods
|
|
WO2026163162A1
(en)
|
2025-01-31 |
2026-08-06 |
Intellia Therapeutics, Inc. |
Enhanced cas9 variants and uses thereof
|
|
WO2026162552A1
(en)
|
2025-01-31 |
2026-08-06 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|